General Court provides guidance on assessing bad faith in ENTEROSGEL case

In invalidity proceedings between Health Product Group and Bioline Pharmaceutical AG, the General Court confirmed that the predecessor in law to Bioline had not acted in bad faith when designating the European Union in respect of the international registration for ENTEROSGEL.

Leave a Comment

Your email address will not be published. Required fields are marked *

20 − nine =